Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Clonal Cytopenia of Undetermined Significance × canakinumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Primary Myelofibrosis 1 Myelodysplastic Syndromes 1 Melanoma 1 Leukemia, Myelomonocytic, Chronic 1 Clonal Cytopenia of Undetermined Significance 1

Interventions

canakinumab 1 X-Rays 1 Specimen Handling 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting

Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon ⚡